sildenafil citrate · Cmp Dev Llc · NDA 214952
Liqrev
Earliest generic entry, as listed
24 Dec 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11337979, US 11464778, US 11759468, US 12005062, US 12186321.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11337979 | drug product, use U-3582 · sets the listed date | 24 Dec 2038 |
| US 11464778 | drug product, use U-3582 · sets the listed date | 24 Dec 2038 |
| US 11759468 | drug product, use U-3582 · sets the listed date | 24 Dec 2038 |
| US 12005062 | drug product, use U-3582 · sets the listed date | 24 Dec 2038 |
| US 12186321 | drug product, use U-3582 · sets the listed date | 24 Dec 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214952 · 001 · RLD · discontinued | suspension, oral | EQ 10MG BASE/ML | 24 Dec 2038 |